# Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

> **NCT00309946** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (actual)

## Conditions studied

- Advanced Malignant Mesothelioma
- Epithelial Mesothelioma
- Localized Malignant Mesothelioma
- Recurrent Malignant Mesothelioma
- Sarcomatous Mesothelioma

## Interventions

- **DRUG:** cediranib maleate

## Key facts

- **NCT ID:** NCT00309946
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00309946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00309946, "Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00309946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*